Praziquantel for the treatment of schistosomiasis: its use for control in areas with endemic disease and prospects for drug resistance

References

• Chitsulo L, Engels D, Montresor A, Savioli L. The global status of schistosomiasis and its control. Acta Tropica77(1), 41–51 (2000).
   PubMed Web of Science ®Google Scholar
• Engels D, Chitsulo L, Montresor A, Savioli L. The global epidemiological situation of schistosomiasis and new approaches to control and research. Acta Tropica82(2), 139–146 (2002).
   PubMed Web of Science ®Google Scholar
• van der Werf MJ, de Vlas SJ, Brooker S et al. Quantification of clinical morbidity associated with schistosome infection in sub-Saharan Africa. Acta Tropica86(2–3), 125–139 (2003).
   PubMed Web of Science ®Google Scholar
• Whitty CJM, Mabey DC, Armstrong M, Wright SG, Chiodini PL. Presentation and outcome of 1107 cases of schistosomiasis from Africa diagnosed in a non-endemic country. Trans. R. Soc. Trop. Med. Hyg.94(5), 531–534 (2000).
   PubMed Web of Science ®Google Scholar
• Southgate VR. Schistosomiasis in the Senegal river basin: before and after the construction of the dams at Diama, Senegal and Manantali, Mali and future prospects. J. Helminthol.71(2), 125–132 (1997).
   PubMed Web of Science ®Google Scholar
• Anderson RM, May RM.Infectious Diseases of Humans: Dynamics and Control. Oxford University Press, UK (1992).
   Google Scholar
• Christopherson JB. The successful use of antimony in bilharziosis. Administration as intravenous injections of antimonium tartaratum (tartar emetic). Lancetii, 325–327 (1918).
   Google Scholar
• Cioli D, Pica-Mattoccia L, Archer S. Antischistosomal drugs – past, present... and future. Pharmacol. Ther.68(1), 35–85 (1995).
   PubMed Web of Science ®Google Scholar
• Chen MG. Use of praziquantel for clinical treatment and morbidity control of schistosomiasis japonica in China: a review of 30 years’ experience. Acta Trop.96(2–3), 168–176 (2005).
   PubMed Web of Science ®Google Scholar
• Hagan P, Appleton CC, Coles GC, Kusel JR, Tchuem-Tchuente LA. Schistosomiasis control: keep taking the tablets. Trends Parasitol.20(2), 92–97 (2004).
   PubMed Web of Science ®Google Scholar
• Cioli D, Pica-Mattoccia L. Praziquantel. Parasitol. Res.90(Suppl. 1), S3–S9 (2003).
   PubMed Web of Science ®Google Scholar
• Fenwick A, Savioli L, Engels D, Robert Bergquist N, Todd MH. Drugs for the control of parasitic diseases: current status and development in schistosomiasis. Trends Parasitol.19(11), 509–515 (2003).
   PubMed Web of Science ®Google Scholar
• Doenhoff MJ, Kusel JR, Coles GC, Cioli D. Resistance of Schistosoma mansoni to praziquantel: is there a problem? Trans. R. Soc. Trop. Med. Hyg.96(5), 465–469 (2002).
   PubMed Web of Science ®Google Scholar
• Fenwick A, Rollinson D, Southgate V. Implementation of human schistosomiasis control: challenges and prospects.Adv. Parasitol. (2006) (In press).
   PubMedGoogle Scholar
• Groll E. Praziquantel. Adv. Pharmacol. Chemother.20, 219–238 (1984).
   PubMedGoogle Scholar
• Seubert J, Pohlke R, Loebich F. Synthesis and properties of praziquantel, a novel broad-spectrum anthelmintic with excellent activity against schistosomes and cestodes. Experientia33(8), 1036–1037 (1977).
   PubMedGoogle Scholar
• Gonnert R, Andrews P. Praziquantel, a new broad-spectrum antischistosomal agent. Z. Parasitenkd.52(2), 129–150 (1977).
   PubMed Web of Science ®Google Scholar
• Katz N, Rocha RS, Chaves A. Preliminary trials with praziquantel in human infections due to Schistosoma mansoni. Bull. World Health Organ.57(5), 781–785 (1979).
   PubMed Web of Science ®Google Scholar
• Davis A, Biles JE, Ulrich AM. Initial experiences with praziquantel in the treatment of human infections due to Schistosoma haematobium. Bull. World Health Organ.57(5), 773–779 (1979).
   PubMed Web of Science ®Google Scholar
• Ishizaki T, Kamo E, Boehme K. Double-blind studies of tolerance to praziquantel in Japanese patients with Schistosoma japonicum infections. Bull. World Health Organ.57(5), 787–791 (1979).
   PubMed Web of Science ®Google Scholar
• Andrews P, Thomas H, Pohlke R, Seubert J. Praziquantel. Med. Res. Rev.3(2), 147–200 (1983).
   PubMed Web of Science ®Google Scholar
• Liu YH, Qian MX, Wang XG et al. Comparative efficacy of praziquantel and its optic isomers in experimental-therapy of schistosomiasis japonica in rabbits. Chin. Med. J.99(12), 935–940 (1986).
   PubMed Web of Science ®Google Scholar
• Wu MH, Wei CC, Xu ZY et al. Comparative efficacy of levo-praziquantel and praziquantel in treatment of schistosomiasis japonica at a single dose. Chin. Med. J.104(9), 732–735 (1991).
   PubMed Web of Science ®Google Scholar
• Savioli L, Engels D, Roungou JB, Fenwick A, Endo H. Schistosomiasis control. Lancet363(9409), 658–658 (2004).
   PubMedGoogle Scholar
• Doenhoff M, Kimani G, Cioli D. Praziquantel and the control of schistosomiasis. Parasitol. Today16(9), 364–366 (2000).
   PubMedGoogle Scholar
• Appleton CC, Mbaye A. Praziquantel – quality, dosages and markers of resistance. Trends Parasitol.17(8), 356–357 (2001).
   PubMedGoogle Scholar
• Sulaiman SM, Traore M, Engels D, Hagan P, Cioli D. Counterfeit praziquantel. Lancet358(9282), 666–667 (2001).
   PubMed Web of Science ®Google Scholar
• WHO. Prevention and control of schistosomiasis and soil-transmitted helminthiasis; report of a WHO Expert Committee. WHO Technical Report Series No. 912. WHO, Geneva, Switzerland (2002).
   Google Scholar
• N’Goran EK, Gnaka HN, Tanner M, Utzinger J. Efficacy and side-effects of two praziquantel treatments against Schistosoma haematobium infection, among schoolchildren from Cote d’Ivoire. Ann. Trop. Med. Parasitol.97(1), 37–51 (2003).
   PubMed Web of Science ®Google Scholar
• Castro N, Medina R, Sotelo J, Jung H. Bioavailability of praziquantel increases with concomitant administration of food. Antimicrob. Agents Chemother.44(10), 2903–2904 (2000).
   PubMed Web of Science ®Google Scholar
• Valencia CI, Catto BA, Webster LT, Barcelon E, Ofendo-Reyes R. Concentration time course of praziquantel in Filipinos with mild Schistosoma japonicum infection. Southeast Asian J. Trop. Med. Public Health25, 409–414 (1994).
   PubMedGoogle Scholar
• Leopold G, Ungethum W, Groll E, Diekmann HW, Nowak H, Wegner DHG. Clinical pharmacology in normal volunteers of praziquantel, a new drug against schistosomes and cestodes – example of a complex study covering both tolerance and pharmacokinetics. Eur. J. Clin. Pharmacol.14(4), 281–291 (1978).
   PubMed Web of Science ®Google Scholar
• Mandour MEM, Elturabi H, Homeida MMA et al. Pharmacokinetics of praziquantel in healthy-volunteers and patients with schistosomiasis. Trans. R. Soc. Trop. Med. Hyg.84(3), 389–393 (1990).
   PubMed Web of Science ®Google Scholar
• Webbe G, James C. Comparison of susceptibility to praziquantel of Schistosoma haematobium, Schistosoma japonicum, S. mansoni, Schistosoma intercalatum and Schistosoma mattheei in hamsters. Z. Parasitenkd.52(2), 169–177 (1977).
   PubMed Web of Science ®Google Scholar
• Wegner DHG. The profile of the trematodicidal compound praziquantel. Arzneimittelforschung34–2(9B), 1132–1136 (1984).
   Web of Science ®Google Scholar
• Sabah AA, Fletcher C, Webbe G, Doenhoff MJ. Schistosoma mansoni – chemotherapy of infections of different ages. Exp. Parasitol.61(3), 294–303 (1986).
   PubMed Web of Science ®Google Scholar
• Xiao SH, Catto BA, Webster LT. Effects of praziquantel on different developmental stages of Schistosoma mansoni in vitro and in vivo. J. Infect. Dis.151(6), 1130–1137 (1985).
   PubMed Web of Science ®Google Scholar
• Pica-Mattoccia L, Cioli D. Sex- and stage-related sensitivity of Schistosoma mansoni to in vivo and in vitro praziquantel treatment. Int. J. Parasitol.34(4), 527–533 (2004).
   PubMed Web of Science ®Google Scholar
• Xiao SH. Development of antischistosomal drugs in China, with particular consideration to praziquantel and the artemisinins. Acta Tropica.96(2–3), 153–167 (2005).
   PubMed Web of Science ®Google Scholar
• Botros S, Pica-Mattoccia L, William S, El-Lakkani N, Cioli D. Effect of praziquantel on the immature stages of Schistosoma haematobium. Int. J. Parasitol.35(13), 1453–1457 (2005).
   PubMed Web of Science ®Google Scholar
• Andrews P. Praziquantel: mechanisms of anti-schistosomal activity. Pharmacol. Ther.29(1), 129–156 (1985).
   PubMed Web of Science ®Google Scholar
• Patzschke K, Putter J, Wegner LA, Horster FA, Diekmann HW. Serum concentrations and renal excretion in humans after oral administration of praziquantel – results of three determination methods. Eur. J. Drug Metab. Pharmacokinet.4(3), 149–156 (1979).
   PubMedGoogle Scholar
• Steiner K, Garbe A, Diekmann HW, Novak H. The fate of praziquantel in the organism. I: pharmacokinetics in animals. Eur. J. Drug Metab. Pharmacokinet.1, 85–95 (1976).
   Google Scholar
• Masimirembwa CM, Hasler JA. Characterization of praziquantel metabolism by rat-liver microsomes using cytochrome-P450 inhibitors. Biochem. Pharmacol.48(9), 1779–1783 (1994).
   PubMed Web of Science ®Google Scholar
• Jung H, Medina R, Castro N, Corona T, Sotelo J. Pharmacokinetic study of praziquantel administered alone and in combination with cimetidine in a single-day therapeutic regimen. Antimicrob. Agents Chemother.41(6), 1256–1259 (1997).
   PubMed Web of Science ®Google Scholar
• El Guiniady MA, El Touny MA, Abdelbary MA, Abdelfatah SA, Metwally A. Clinical and pharmacokinetic study of praziquantel in Egyptian schistosomiasis patients with and without liver-cell failure. Am. J. Trop. Med. Hyg.51(6), 809–818 (1994).
   PubMed Web of Science ®Google Scholar
• Wang FX, Zhu YQ, Yao QS et al. Effect in vitro of metabolites of praziquantel on Schistosoma japonicum. Zhongguo Yao Li Xue Bao4(1), 45–48 (1983).
   PubMedGoogle Scholar
• Frohberg H. Results of toxicological studies on praziquantel. Arzneimittelforschung34–2(9B), 1137–1144 (1984).
   Web of Science ®Google Scholar
• Kramers PGN, Gentile JM, Gryseels BJAM et al. Review of the genotoxicity and carcinogenicity of antischistosomal drugs – is there a case for a study of mutation epidemiology – report of a task group on mutagenic antischistosomals. Mutat. Res.257(1), 49–89 (1991).
   PubMed Web of Science ®Google Scholar
• Ketkar M, Althoff J, Mohr U. A chronic study of praziquantel in Syrian golden hamsters and Sprague-Dawley rats. Toxicology24(3–4), 345–350 (1982).
   PubMed Web of Science ®Google Scholar
• Montero R, Ostrosky P. Genotoxic activity of praziquantel. Mutat. Res.387(3), 123–139 (1997).
   PubMed Web of Science ®Google Scholar
• Bassily S, Farid Z, Dunn M, Elmasry NA, Stek M. Praziquantel for treatment of schistosomiasis in patients with advanced hepatosplenomegaly. Ann. Trop. Med. Parasitol.79(6), 629–634 (1985).
   PubMed Web of Science ®Google Scholar
• Allen HE, Crompton DW, de Silva N, LoVerde PT, Olds GR. New policies for using anthelmintics in high risk groups. Trends Parasitol.18(9), 381–382 (2002).
   PubMedGoogle Scholar
• Jaoko WG, Muchemi G, Oguya FO. Praziquantel side effects during treatment of Schistosoma mansoni infected pupils in Kibwezi, Kenya. East Afr. Med. J.73(8), 499–501 (1996).
   PubMed Web of Science ®Google Scholar
• Berhe N, Gundersen SG, Abebe F, Birrie H, Medhin G, Gemetchu T. Praziquantel side effects and efficacy related to Schistosoma mansoni egg loads and morbidity in primary school children in north-east Ethiopia. Acta Trop.72(1), 53–63 (1999).
   PubMed Web of Science ®Google Scholar
• Polderman AM, Gryseels B, Gerold JL, Mpamila K, Manshande JP. Side effects of praziquantel in the treatment of Schistosoma mansoni in Maniema, Zaire. Trans. R. Soc. Trop. Med. Hyg.78(6), 752–754 (1984).
   PubMed Web of Science ®Google Scholar
• Pax R, Bennett JL, Fetterer R. A benzodiazine derivative and praziquantel: effects on musculature of Schistosoma mansoni and Schistosoma japonicum. Naunyn Schiedbergs Arch. Pharmacol.304, 309–315 (1978).
   PubMed Web of Science ®Google Scholar
• Nechay BR, Hillman GR, Dotson MJ. Properties and drug sensitivity of adenosine triphosphatases from Schistosoma mansoni. J. Parasitol.66(4), 596–600 (1980).
   PubMed Web of Science ®Google Scholar
• Becker B, Mehlhorn H, Andrews P, Thomas H, Eckert J. Light and electron microscopic studies on the effect of praziquantel on Schistosoma mansoni, Dicrocoelium dendriticum, and Fasciola hepatica (Trematoda) in vitro. Z Parasitenkd.63(2), 113–128 (1980).
   PubMed Web of Science ®Google Scholar
• Mehlhorn H, Becker B, Andrews P, Thomas H, Frenkel JK. In vivo and in vitro experiments on the effects of praziquantel on Schistosoma mansoni. A light and electron microscopic study. Arzneimittelforschung31(3a), 544–554 (1981).
   PubMed Web of Science ®Google Scholar
• Harnett W, Kusel JR. Increased exposure of parasite antigens at the surface of adult male Schistosoma mansoni exposed to praziquantel in vitro. Parasitology93(Pt 2), 401–405 (1986).
   PubMed Web of Science ®Google Scholar
• Sabah AA, Fletcher C, Webbe G, Doenhoff MJ. Schistosoma mansoni: reduced efficacy of chemotherapy in infected T-cell-deprived mice. Exp. Parasitol.60(3), 348–354 (1985).
   PubMed Web of Science ®Google Scholar
• Brindley PJ, Sher A. The chemotherapeutic effect of praziquantel against Schistosoma mansoni is dependent on host antibody response. J. Immunol.139(1), 215–220 (1987).
   PubMed Web of Science ®Google Scholar
• Doenhoff MJ, Sabah AA, Fletcher C, Webbe G, Bain J. Evidence for an immune-dependent action of praziquantel on Schistosoma mansoni in mice. Trans. R. Soc. Trop. Med. Hyg.81(6), 947–951 (1987).
   PubMed Web of Science ®Google Scholar
• Doenhoff MJ, Modha J, Lambertucci JR. Anti-schistosome chemotherapy enhanced by antibodies specific for a parasite esterase. Immunology65(4), 507–510 (1988).
   PubMed Web of Science ®Google Scholar
• Brindley PJ, Sher A. Immunological involvement in the efficacy of praziquantel. Exp. Parasitol.71(2), 245–248 (1990).
   PubMed Web of Science ®Google Scholar
• Karanja DM, Boyer AE, Strand M et al. Studies on schistosomiasis in western Kenya: II. Efficacy of praziquantel for treatment of schistosomiasis in persons coinfected with human immunodeficiency virus-1. Am. J. Trop. Med. Hyg.59(2), 307–311 (1998).
   PubMed Web of Science ®Google Scholar
• Bricker CS, Depenbusch JW, Bennett JL, Thompson DP. The relationship between tegumental disruption and muscle contraction in Schistosoma mansoni exposed to various compounds. Z Parasitenkd.69(1), 61–71 (1983).
   PubMed Web of Science ®Google Scholar
• Harder A, Goossens J, Andrews P. Influence of praziquantel and Ca2+ on the bilayer-isotropic-hexagonal transition of model membranes. Mol. Biochem. Parasitol.29(1), 55–59 (1988).
   PubMed Web of Science ®Google Scholar
• Schepers H, Brasseur R, Goormaghtigh E, Duquenoy P, Ruysschaert JM. Mode of insertion of praziquantel and derivatives into lipid membranes. Biochem. Pharmacol.37(8), 1615–1623 (1988).
   PubMed Web of Science ®Google Scholar
• McTigue MA, Williams DR, Tainer JA. Crystal structures of a schistosomal drug and vaccine target: glutathione S-transferase from Schistosoma japonica and its complex with the leading antischistosomal drug praziquantel. J. Mol. Biol.246(1), 21–27 (1995).
   PubMed Web of Science ®Google Scholar
• Milhon JL, Thiboldeaux RL, Glowac K, Tracy JW. Schistosoma japonicum GSH S-transferase Sj26 is not the molecular target of praziquantel action. Exp. Parasitol.87(3), 268–274 (1997).
   PubMed Web of Science ®Google Scholar
• Greenberg RM. Are Ca2+ channels targets of praziquantel action? Int. J. Parasitol.35(1), 1–9 (2005).
   PubMed Web of Science ®Google Scholar
• Kohn AB, Anderson PA, Roberts-Misterly JM, Greenberg RM. Schistosome calcium channel beta subunits. Unusual modulatory effects and potential role in the action of the antischistosomal drug praziquantel. J. Biol. Chem.276(40), 36873–36876 (2001).
   PubMed Web of Science ®Google Scholar
• Kohn AB, Roberts-Misterly JM, Anderson PA, Greenberg RM. Creation by mutagenesis of a mammalian Ca(2+) channel beta subunit that confers praziquantel sensitivity to a mammalian Ca(2+) channel. Int. J. Parasitol.33(12), 1303–1308 (2003).
   PubMed Web of Science ®Google Scholar
• Kohn AB, Roberts-Misterly JM, Anderson PA, Khan N, Greenberg RM. Specific sites in the beta interaction domain of a schistosome Ca2+ channel beta subunit are key to its role in sensitivity to the anti-schistosomal drug praziquantel. Parasitology127(Pt 4), 349–356 (2003).
   PubMed Web of Science ®Google Scholar
• Cioli D, Pica-Mattoccia L, Archer S. Drug resistance in schistosomes. Parasitol. Today9(5), 162–166 (1993).
   PubMedGoogle Scholar
• WHO. Report of the WHO informal consultation on schistosomiasis in low transmission areas: control strategies and criteria for elimination. WHO, Geneva, Switzerland (2001).
   Google Scholar
• Magnussen P. Treatment and re-treatment strategies for schistosomiasis control in different epidemiological settings: a review of 10 years’ experiences. Acta Tropica86(2–3), 243–254 (2003).
   PubMed Web of Science ®Google Scholar
• Utzinger J, Bergquist R, Shu-Hua X, Singer BH, Tanner M. Sustainable schistosomiasis control – the way forward. Lancet362(9399), 1932–1934 (2003).
   PubMed Web of Science ®Google Scholar
• El-Khoby T, Galal N, Fenwick A. The USAID Government of Egypt’s Schistosmiasis Research Project (SRP). Parasitol. Today14, 92–96 (1998).
   PubMedGoogle Scholar
• Gryseels B. The relevance of schistosomiasis for public health. Trop. Med. Parasitol.40(2), 134–142 (1989).
   PubMedGoogle Scholar
• Secor WE. Immunology of human schistosomiasis: off the beaten path. Parasite Immunol.27(7–8), 309–316 (2005).
   PubMed Web of Science ®Google Scholar
• King CH, Dickman K, Tisch DJ. Reassessment of the cost of chronic helmintic infection: a meta-analysis of disability-related outcomes in endemic schistosomiasis. Lancet365(9470), 1561–1569 (2005).
   PubMed Web of Science ®Google Scholar
• Bergquist NR, Leonardo LR, Mitchell GF. Vaccine-linked chemotherapy: can schistosomiasis control benefit from an integrated approach? Trends Parasitol.21(3), 112–117 (2005).
   PubMed Web of Science ®Google Scholar
• Fenwick A. New initiatives against Africa’s worms. Trans. R. Soc. Trop. Med. Hyg.100(3), 200–207 (2006).
   PubMed Web of Science ®Google Scholar
• Southgate VR, Rollinson D, Tchuem Tchuente LA, Hagan P. Towards control of schistosomiasis in sub-Saharan Africa. J. Helminthol.79(3), 181–185 (2005).
   PubMed Web of Science ®Google Scholar
• Kabatereine NB, Tukahebwa E, Kazibwe F et al. Progress towards countrywide control of schistosomiasis and soil-transmitted helminthiasis in Uganda. Trans. R. Soc. Trop. Med. Hyg.100(3), 208–215 (2006).
   PubMed Web of Science ®Google Scholar
• Stelma FF, Talla I, Polman K et al. Epidemiology of Schistosoma mansoni infection in a recently exposed community in northern Senegal. Am. J. Trop. Med. Hyg.49(6), 701–706 (1993).
   PubMed Web of Science ®Google Scholar
• Gryseels B, Stelma FF, Talla I et al. Epidemiology, immunology and chemotherapy of Schistosoma mansoni infections in a recently exposed community in Senegal. Trop. Geogr. Med.46(4 Spec. No.), 209–219 (1994).
   PubMedGoogle Scholar
• Stelma FF, Talla I, Sow S et al. Efficacy and side effects of praziquantel in an epidemic focus of Schistosoma mansoni. Am. J. Trop. Med. Hyg.53(2), 167–170 (1995).
   PubMed Web of Science ®Google Scholar
• Guisse F, Polman K, Stelma FF et al. Therapeutic evaluation of two different dose regimens of praziquantel in a recent Schistosoma mansoni focus in Northern Senegal. Am. J. Trop. Med. Hyg.56(5), 511–514 (1997).
   PubMed Web of Science ®Google Scholar
• Tchuem Tchuente LA, Southgate VR, Mbaye A, Engels D, Gryseels B. The efficacy of praziquantel against Schistosoma mansoni infection in Ndombo, northern Senegal. Trans. R. Soc. Trop. Med. Hyg.95(1), 65–66 (2001).
   PubMed Web of Science ®Google Scholar
• Fallon PG, Sturrock RF, Niang AC, Doenhoff MJ. Short report: diminished susceptibility to praziquantel in a Senegal isolate of Schistosoma mansoni. Am. J. Trop. Med. Hyg.53(1), 61–62 (1995).
   PubMed Web of Science ®Google Scholar
• Fallon PG, Mubarak JS, Fookes RE et al. Schistosoma mansoni: maturation rate and drug susceptibility of different geographic isolates. Exp. Parasitol.86(1), 29–36 (1997).
   PubMed Web of Science ®Google Scholar
• Liang YS, Coles GC, Doenhoff MJ, Southgate VR. In vitro responses of praziquantel-resistant and -susceptible Schistosoma mansoni to praziquantel. Int. J. Parasitol.31(11), 1227–1235 (2001).
   PubMed Web of Science ®Google Scholar
• Stelma FF, Sall S, Daff B, Sow S, Niang M, Gryseels B. Oxamniquine cures Schistosoma mansoni infection in a focus in which cure rates with praziquantel are unusually low. J. Infect. Dis.176(1), 304–307 (1997).
   PubMed Web of Science ®Google Scholar
• Ismail M, Metwally A, Farghaly A, Bruce J, Tao LF, Bennett JL. Characterization of isolates of Schistosoma mansoni from Egyptian villagers that tolerate high doses of praziquantel. Am. J. Trop. Med. Hyg.55(2), 214–218 (1996).
   PubMed Web of Science ®Google Scholar
• Ismail M, Botros S, Metwally A et al. Resistance to praziquantel: direct evidence from Schistosoma mansoni isolated from Egyptian villagers. Am. J. Trop. Med. Hyg.60(6), 932–935 (1999).
   PubMed Web of Science ®Google Scholar
• William S, Botros S. Validation of sensitivity to praziquantel using Schistosoma mansoni worm muscle tension and Ca2+-uptake as possible in vitro correlates to in vivo ED50 determination. Int. J. Parasitol.34(8), 971–977 (2004).
   PubMed Web of Science ®Google Scholar
• William S, Botros S, Ismail M, Farghally A, Day TA, Bennett JL. Praziquantel-induced tegumental damage in vitro is diminished in schistosomes derived from praziquantel-resistant infections. Parasitology122(Pt 1), 63–66 (2001).
   Google Scholar
• Fallon PG, Doenhoff MJ. Drug-resistant schistosomiasis: resistance to praziquantel and oxamniquine induced in Schistosoma mansoni in mice is drug specific. Am. J. Trop. Med. Hyg.51(1), 83–88 (1994).
   PubMed Web of Science ®Google Scholar
• Cioli D, Botros SS, Wheatcroft-Francklow K et al. Determination of ED50 values for praziquantel in praziquantel-resistant and -susceptible Schistosoma mansoni isolates. Int. J. Parasitol.34(8), 979–987 (2004).
   PubMed Web of Science ®Google Scholar
• Pereira C, Fallon PG, Cornette J, Capron A, Doenhoff MJ, Pierce RJ. Alterations in cytochrome-C oxidase expression between praziquantel-resistant and susceptible strains of Schistosoma mansoni. Parasitology117(Pt 1), 63–73 (1998).
   PubMed Web of Science ®Google Scholar
• Tsai MH, Marx KA, Ismail MM, Tao L. Randomly amplified polymorphic DNA (RAPD) polymerase chain reaction assay for identification of Schistosoma mansoni strains sensitive or tolerant to anti-schistosomal drugs. J. Parasitol.86(1), 146–149 (2000).
   PubMed Web of Science ®Google Scholar
• Valle C, Troiani AR, Festucci A et al. Sequence and level of endogenous expression of calcium channel beta subunits in Schistosoma mansoni displaying different susceptibilities to praziquantel. Mol. Biochem. Parasitol.130(2), 111–115 (2003).
   PubMed Web of Science ®Google Scholar
• Liang YS, Coles GC, Dai JR, Zhu YC, Doenhoff MJ. Adult worm tegumental damage and egg-granulomas in praziquantel-resistant and -susceptible Schistosoma mansoni treated in vivo. J. Helminthol.76(4), 327–333 (2002).
   PubMed Web of Science ®Google Scholar
• Danso-Appiah A, De Vlas SJ. Interpreting low praziquantel cure rates of Schistosoma mansoni infections in Senegal. Trends Parasitol.18(3), 125–129 (2002).
   PubMed Web of Science ®Google Scholar
• Renganathan E, Cioli D. An international initiative on praziquantel use. Parasitol. Today14(10), 390–391 (1998).
   PubMedGoogle Scholar
• Gryseels B, Mbaye A, De Vlas SJ et al. Are poor responses to praziquantel for the treatment of Schistosoma mansoni infections in Senegal due to resistance? An overview of the evidence. Trop. Med. Int. Health6(11), 864–873 (2001).
   PubMed Web of Science ®Google Scholar
• Utzinger J, N’Goran EK, N’Dri A, Lengeler C, Tanner M. Efficacy of praziquantel against Schistosoma mansoni with particular consideration for intensity of infection. Trop. Med. Int. Health5(11), 771–778 (2000).
   PubMed Web of Science ®Google Scholar
• Botros S, Sayed H, Amer N, El-Ghannam M, Bennett JL, Day TA. Current status of sensitivity to praziquantel in a focus of potential drug resistance in Egypt. Int. J. Parasitol.35(7), 787–791 (2005).
   PubMed Web of Science ®Google Scholar
• William S, Sabra A, Ramzy F et al. Stability and reproductive fitness of Schistosoma mansoni isolates with decreased sensitivity to praziquantel. Int. J. Parasitol.31(10), 1093–1100 (2001).
   PubMed Web of Science ®Google Scholar
• Martin PJ, Le Jambre LF, Claxton JH. The impact of refugia on the development of thiabendazole resistance in Haemonchus contortus. Int. J. Parasitol.11(1), 35–41 (1981).
   PubMed Web of Science ®Google Scholar
• van Wyk JA. Refugia – overlooked as perhaps the most potent factor concerning the development of anthelmintic resistance. Onderstepoort J. Vet. Res.68(1), 55–67 (2001).
   PubMed Web of Science ®Google Scholar
• Coles GC. Sustainable use of anthelmintics in grazing animals. Vet. Rec.151(6), 165–169 (2002).
   PubMed Web of Science ®Google Scholar
• Kabatereine NB, Kemijumbi J, Ouma JH et al. Efficacy and side effects of praziquantel treatment in a highly endemic Schistosoma mansoni focus at Lake Albert, Uganda. Trans. R. Soc. Trop. Med. Hyg.97(5), 599–603 (2003).
   PubMed Web of Science ®Google Scholar
• Doenhoff MJ, Chiodini PL, Hamilton JV. Specific and sensitive diagnosis of schistosome infection: can it be done with antibodies?Trends Parasitol.20(1), 35–39 (2004).
   PubMed Web of Science ®Google Scholar
• Doenhoff MJ. Is schistosomicidal chemotherapy sub-curative? Implications for drug resistance. Parasitol. Today14(10), 434–435 (1998).
   PubMedGoogle Scholar
• Lawn SD, Lucas SB, Chiodini PL. Case report: Schistosoma mansoni infection: failure of standard treatment with praziquantel in a returned traveller. Trans. R. Soc. Trop. Med. Hyg.97(1), 100–101 (2003).
   PubMed Web of Science ®Google Scholar
• Alonso D, Munoz J, Gascon J, Valls ME, Corachan M. Failure of standard treatment with praziquantel in two returned travelers with Schistosoma haematobium infection. Am. J. Trop. Med. Hyg.74(2), 342–344 (2006).
   PubMed Web of Science ®Google Scholar
• N’Goran EK, Utzinger J, Gnaka HN et al. Randomized, double-blind, placebo-controlled trial of oral artemether for the prevention of patent Schistosoma haematobium infections. Am. J. Trop. Med. Hyg.68(1), 24–32 (2003).
   PubMed Web of Science ®Google Scholar
• Li YS, Chen HG, He HB, Hou XY, Ellis M, McManus DP. A double-blind field trial on the effects of artemether on Schistosoma japonicum infection in a highly endemic focus in southern China. Acta Trop.96(2–3), 184–190 (2005).
   PubMed Web of Science ®Google Scholar
• Utzinger J, Chollet J, Tu Z, Xiao S, Tanner M. Comparative study of the effects of artemether and artesunate on juvenile and adult Schistosoma mansoni in experimentally infected mice. Trans. R. Soc. Trop. Med. Hyg.96(3), 318–323 (2002).
   PubMed Web of Science ®Google Scholar
• Ashley EA, White NJ. Artemisinin-based combinations. Curr. Opin. Infect. Dis.18(6), 531–536 (2005).
   PubMed Web of Science ®Google Scholar
• Yang ZS, Wu WM, Li Y, Wu YL. Design and synthesis of novel artemisinin-like ozonides with antischistosomal activity. Helvetica Chimica Acta88(11), 2865–2872 (2005).
   Web of Science ®Google Scholar
• Sheir Z, Nasr AA, Massoud A et al. A safe, effective, herbal antischistosomal therapy derived from myrrh. Am. J. Trop. Med. Hyg.65(6), 700–704 (2001).
   PubMed Web of Science ®Google Scholar
• Botros S, William S, Ebeid F et al. Lack of evidence for an antischistosomal activity of myrrh in experimental animals. Am. J. Trop. Med. Hyg.71(2), 206–210 (2004).
   PubMed Web of Science ®Google Scholar
• Barakat R, Elmorshedy H, Fenwick A. Efficacy of myrrh in the treatment of human schistosomiasis mansoni. Am. J. Trop. Med. Hyg.73(2), 365–367 (2005).
   PubMed Web of Science ®Google Scholar
• Botros S, Sayed H, El-Dusoki H et al. Efficacy of mirazid in comparison with praziquantel in Egyptian Schistosoma mansoni-infected school children and households. Am. J. Trop. Med. Hyg.72(2), 119–123 (2005).
   PubMed Web of Science ®Google Scholar
• Druilhe P, Tall A, Sokhna C. Worms can worsen malaria: towards a new means to roll back malaria? Trends Parasitol.21(8), 359–362 (2005).
   PubMed Web of Science ®Google Scholar
• Fenwick A, Molyneux D, Nantulya V. Achieving the millennium development goals. Lancet365(9464), 1029–1030 (2005).
   PubMed Web of Science ®Google Scholar
• Molyneux DH, Hotez PJ, Fenwick A. ‘Rapid-impact interventions’: how a policy of integrated control for Africa’s neglected tropical diseases could benefit the poor. PLoS Med.2(11), e336 (2005).
   PubMed Web of Science ®Google Scholar